Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IOV-4001 by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
IOV-4001 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Data Insights
IOV-4001 by Iovance Biotherapeutics for Metastatic Melanoma: Likelihood of Approval
IOV-4001 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...